Amniotics Q1 2023: NK-program Initiated but under Financial Strain - Redeye

Amniotics finished the clinical trial of Pulmostem in Q1 and is now analysing the data. The grant for the NK cell-based therapies project was paid to Amniotics as leader of the consortium. Amniotics also received some cash from the rights issue. However, the net cash position will not finance the company through the rest of the year.

Länk till analysen i sin helhet: https://www.redeye.se/research/903286/amniotics-q1-2023-nk-program-initiated-but-under-financial-strain?utm_source=finwire&utm_medium=RSS